FDA has approved obinutuzumab (Gazyva) to induce remission of proteinuria in adults with primary membranous nephropathy (pMN) who are at risk of disease progression, Roche announced on November 16, 2026.¹ According to the company, it is the first FDA-approved therapy for pMN, a chronic autoimmune kidney disease. Obinutuzumab had previously received breakthrough therapy designation for this use, and FDA granted the supplemental application priority review in July 2026.¹
Key facts
- Drug: obinutuzumab (Gazyva; Roche)
- Class: Type II anti-CD20 humanized monoclonal antibody (glycoengineered Fc)
- Indication: Adults with pMN at risk of disease progression, to induce remission of proteinuria
- Trial: MAJESTY (NCT04629248); phase 3, randomized, open-label, n=142
- Primary end point met: Complete remission at week 104, 36.1% vs 5.7% with tacrolimus
- Secondary end points: Overall remission 50% vs 12.9%; complete remission at week 76, 36.1% vs 8.6%
- Safety: Consistent with known profile; no new safety signals
- Approval: FDA, announced November 16, 2026; first approved therapy for pMN
- Prior designation: Breakthrough therapy
- Other kidney approvals: Lupus nephritis; idiopathic nephrotic syndrome (US)
“The FDA approval of Gazyva/Gazyvaro represents an important step forward for people living with primary membranous nephropathy, where targeting B cells addresses a critical underlying driver of disease,” said Levi Garraway, MD, PhD, Roche's chief medical officer and head of global product development, in a company press release.¹
What did the MAJESTY trial show?
The approval is based on the phase 3 MAJESTY study (NCT04629248). This randomized, open-label, multicenter trial enrolled 142 adults with pMN and randomized them 1:1 to obinutuzumab or tacrolimus.¹,² The trial met its primary end point, in which 36.1% of patients receiving obinutuzumab achieved complete remission of proteinuria at 2 years (week 104) vs 5.7% of those receiving tacrolimus (adjusted difference, 31.1%; 95% confidence interval [CI]: 18.2 to 44.0; p<.001).¹,³
Obinutuzumab was also shown to be superior to tacrolimus on key secondary end points.¹ Overall remission (complete or partial) at week 104 was 50% vs 12.9% (adjusted difference, 37.8%; 95% CI: 23.9 to 51.8; p<.001). Complete remission at week 76 was 36.1% vs 8.6% (adjusted difference, 27.4%; 95% CI: 13.4 to 39.8; p<.001).¹ The results were a late-breaking oral presentation at the 63rd European Renal Association Congress in June 2026 and were published in the New England Journal of Medicine.¹,³
According to Roche, safety in MAJESTY was in line with the established profile of obinutuzumab, and no new safety signals were identified.¹
How does obinutuzumab work?
Obinutuzumab is a humanized monoclonal antibody with 2 engineered features. Its type II anti-CD20 region is designed to kill B cells directly, and its glycoengineered Fc region is designed for higher binding affinity and increased antibody-dependent cellular cytotoxicity.¹ CD20 is a protein found on certain types of B cells. In pMN, the immune system attacks the glomeruli, the kidney's filtering units. This causes protein to leak into the urine and can gradually reduce kidney function.¹
Why does this approval matter?
According to Roche, pMN has an estimated incidence of 1.2 per 100,000 people in the United States per year, and up to 30% of untreated patients progress to kidney failure within 10 years.¹ Complete remission is important to help maintain kidney function and delay or prevent serious complications.¹